ROUND OUT THE TRIO—with significant reduction in daily off time1
In two ~14-week, double-blind studies of patients with PD taking ONGENTYS® (opicapone) capsules + levodopa/DDCI1*:
REDUCED DAILY OFF TIME1,2
Once-daily ONGENTYS significantly reduced off time by 1.95 hours compared to 0.93 hours with placebo (P=0.002) at Week 14/151†
- Decrease in off time was seen as early as 1 week (-1.24 hours vs -0.42 hours for placebo, P=0.002)2‡
- In Study 1, consistent improvements were seen regardless of demographic characteristics, PD severity, and concomitant PD treatments2
†Adjusted P value was calculated using a gatekeeping procedure controlling for multiplicity.1
*82% of patients in both groups were also taking concomitant PD medications in addition to levodopa/DDCI, including dopamine agonists (68%), amantadine (23%), MAO-B inhibitors (20%), and anticholinergics (5%).1
‡P<0.05, not adjusted for multiplicity.2
DDCI=dopa decarboxylase inhibitor; LS=least squares; MAO=monoamine oxidase; PD=Parkinson’s disease; SE=standard error.
REDUCED DAILY OFF TIME1,2
Once-daily ONGENTYS significantly reduced off time by 1.98 hours compared to 1.07 hours with placebo (P=0.008) at Week 14/151†
- Decrease in off time was seen as early as 1 week (-1.22 hours vs -0.47 hours for placebo, P=0.001)2‡
- In Study 2, consistent improvements were seen regardless of demographic characteristics, PD severity, and concomitant PD treatments2
†Adjusted P value was calculated using Dunnett's alpha level adjustment to control for multiplicity.1
*85% of patients taking ONGENTYS and 81% of patients taking placebo were also taking concomitant PD medications in addition to levodopa/DDCI, including dopamine agonists (70%), amantadine (21%), MAO-B inhibitors (20%), and anticholinergics (12%).1
‡P<0.05, not adjusted for multiplicity.2
DDCI=dopa decarboxylase inhibitor; LS=least squares; MAO=monoamine oxidase; PD=Parkinson’s disease; SE=standard error.